Wiek H. Van Gilst

Wiek H. Van Gilst's AcademicInfluence.com Rankings

Wiek H. Van Gilst

Biology

#11128

World Rank

#14504

Historical Rank

Genetics

#1192

World Rank

#1292

Historical Rank

biology Degrees

Download Badge

Biology

Wiek H. Van Gilst's Degrees

PhD Genetics Stanford University
Bachelors Biology University of California, Berkeley

Similar Degrees You Can Earn

Best Online Bachelor's in Biology 2026

Why Is Wiek H. Van Gilst Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Wiek H. Van Gilst's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Genetic Variants in Novel Pathways Influence Blood Pressure and Cardiovascular Disease Risk (2011) (1928)
Urinary Albumin Excretion Predicts Cardiovascular and Noncardiovascular Mortality in General Population (2002) (1585)
The EuroHeart Failure survey programme-- a survey on the quality of care among patients with heart failure in Europe. Part 1: patient characteristics and diagnosis. (2003) (1421)
The EuroHeart Failure Survey programme--a survey on the quality of care among patients with heart failure in Europe. Part 2: treatment. (2003) (724)
Microalbuminuria is common, also in a nondiabetic, nonhypertensive population, and an independent indicator of cardiovascular risk factors and cardiovascular morbidity (2001) (681)
Effects of Fosinopril and Pravastatin on Cardiovascular Events in Subjects With Microalbuminuria (2004) (564)
Effect of moderate or intensive disease management program on outcome in patients with heart failure: Coordinating Study Evaluating Outcomes of Advising and Counseling in Heart Failure (COACH). (2008) (542)
Compliance in heart failure patients: the importance of knowledge and beliefs. (2006) (530)
Prediction of uneventful cardioversion and maintenance of sinus rhythm from direct-current electrical cardioversion of chronic atrial fibrillation and flutter. (1991) (467)
Incidence and epidemiology of new onset heart failure with preserved vs. reduced ejection fraction in a community-based cohort: 11-year follow-up of PREVEND. (2013) (445)
Genetic associations at 53 loci highlight cell types and biological pathways relevant for kidney function (2016) (388)
Ultrasound and Microbubble-Targeted Delivery of Macromolecules Is Regulated by Induction of Endocytosis and Pore Formation (2009) (378)
Genetic and Pharmacological Inhibition of Galectin-3 Prevents Cardiac Remodeling by Interfering With Myocardial Fibrogenesis (2013) (377)
B-type natriuretic peptide and prognosis in heart failure patients with preserved and reduced ejection fraction. (2013) (375)
Common variants in 22 loci are associated with QRS duration and cardiac ventricular conduction (2010) (345)
The fibrosis marker galectin‐3 and outcome in the general population (2012) (343)
Microbubbles and ultrasound: from diagnosis to therapy. (2004) (299)
Serial antiarrhythmic drug treatment to maintain sinus rhythm after electrical cardioversion for chronic atrial fibrillation or atrial flutter. (1991) (277)
Erythropoietin induces neovascularization and improves cardiac function in rats with heart failure after myocardial infarction. (2005) (271)
Telomere length of circulating leukocytes is decreased in patients with chronic heart failure. (2006) (269)
Treating oxidative stress in heart failure: past, present and future (2018) (269)
The relevance of tissue angiotensin-converting enzyme: manifestations in mechanistic and endpoint data. (2001) (267)
Angiotensin-(1–7) Attenuates the Development of Heart Failure After Myocardial Infarction in Rats (2002) (267)
Ion Channel Remodeling Is Related to Intraoperative Atrial Effective Refractory Periods in Patients With Paroxysmal and Persistent Atrial Fibrillation (2001) (258)
Regional myocardial blood flow reserve impairment and metabolic changes suggesting myocardial ischemia in patients with idiopathic dilated cardiomyopathy. (2000) (243)
Telomere biology in healthy aging and disease (2009) (242)
Spinal cord stimulation in chronic intractable angina pectoris: a randomized, controlled efficacy study. (1998) (230)
Erythropoietin improves cardiac function through endothelial progenitor cell and vascular endothelial growth factor mediated neovascularization. (2007) (230)
Mechanisms of atrial structural changes caused by stretch occurring before and during early atrial fibrillation. (2011) (220)
Reduction of reperfusion arrhythmias in the ischemic isolated rat heart by angiotensin converting enzyme inhibitors: a comparison of captopril, enalapril, and HOE 498. (1986) (220)
Alterations in potassium channel gene expression in atria of patients with persistent and paroxysmal atrial fibrillation: differential regulation of protein and mRNA levels for K+ channels. (2001) (217)
The Association of Obesity and Cardiometabolic Traits With Incident HFpEF and HFrEF. (2018) (205)
Glucagon-Like Peptide 1 Prevents Reactive Oxygen Species–Induced Endothelial Cell Senescence Through the Activation of Protein Kinase A (2010) (200)
Incidence of Atrial Fibrillation and Relationship With Cardiovascular Events, Heart Failure, and Mortality: A Community-Based Study From the Netherlands. (2015) (194)
Gene expression of proteins influencing the calcium homeostasis in patients with persistent and paroxysmal atrial fibrillation. (1999) (188)
Prognostic value of plasma erythropoietin on mortality in patients with chronic heart failure. (2004) (187)
Association of genetic variation with systolic and diastolic blood pressure among African Americans: the Candidate Gene Association Resource study (2011) (185)
Protective effects of erythropoietin in cardiac ischemia: from bench to bedside. (2006) (185)
Efficacy and safety of flecainide acetate in the maintenance of sinus rhythm after electrical cardioversion of chronic atrial fibrillation or atrial flutter. (1989) (183)
Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis (2021) (181)
Timing of Erythropoietin Treatment for Cardioprotection in Ischemia/Reperfusion (2004) (178)
Angiotensin-(1-7) is a modulator of the human renin-angiotensin system. (1999) (176)
Accelerated decline and prognostic impact of renal function after myocardial infarction and the benefits of ACE inhibition: the CATS randomized trial. (2003) (176)
Angiotensin II type 1 receptor A1166C gene polymorphism is associated with an increased response to angiotensin II in human arteries. (2000) (173)
Acute conversion of atrial fibrillation to sinus rhythm: clinical efficacy of flecainide acetate. Comparison of two regimens. (1988) (169)
Metformin improves cardiac function in a nondiabetic rat model of post-MI heart failure. (2011) (167)
Association of Cardiovascular Biomarkers With Incident Heart Failure With Preserved and Reduced Ejection Fraction (2018) (163)
Activation of proteolysis by calpains and structural changes in human paroxysmal and persistent atrial fibrillation. (2002) (156)
An international perspective on heart failure and left ventricular systolic dysfunction complicating myocardial infarction: the VALIANT registry. (2004) (154)
Anaemia in chronic heart failure is not only related to impaired renal perfusion and blunted erythropoietin production, but to fluid retention as well. (2006) (153)
Levels of Hematopoiesis Inhibitor N-Acetyl-Seryl-Aspartyl-Lysyl-Proline Partially Explain the Occurrence of Anemia in Heart Failure (2005) (151)
Erythropoietin in cardiovascular diseases. (2004) (149)
Effects of quinapril on clinical outcome after coronary artery bypass grafting (The QUO VADIS Study). QUinapril on Vascular Ace and Determinants of Ischemia. (2001) (145)
Effects of Angiotensin-Converting Enzyme Inhibition in Low-Risk Patients Early After Coronary Artery Bypass Surgery (2008) (145)
A single dose of erythropoietin in ST-elevation myocardial infarction. (2010) (144)
Predicting Heart Failure With Preserved and Reduced Ejection Fraction: The International Collaboration on Heart Failure Subtypes. (2015) (142)
Microalbuminuria is independently associated with ischaemic electrocardiographic abnormalities in a large non-diabetic population. The PREVEND (Prevention of REnal and Vascular ENdstage Disease) study. (2000) (138)
Acute intervention with captopril during thrombolysis in patients with first anterior myocardial infarction. Results from the Captopril and Thrombolysis Study (CATS). (1994) (134)
Pathophysiologic and Therapeutic Importance of Tissue ACE: A Consensus Report (2002) (134)
Determinants of increased angiotensin II levels in severe chronic heart failure patients despite ACE inhibition. (2006) (129)
Angiotensin-(1-7): pharmacological properties and pharmacotherapeutic perspectives. (2008) (126)
Efficacy, safety, and determinants of conversion of atrial fibrillation and flutter with oral amiodarone. (1997) (121)
Early and late effects of the DPP-4 inhibitor vildagliptin in a rat model of post-myocardial infarction heart failure (2011) (116)
Galectin-3, Renal Function, and Clinical Outcomes: Results from the LURIC and 4D Studies. (2015) (114)
Cost-effectiveness of screening for albuminuria with subsequent fosinopril treatment to prevent cardiovascular events: A pharmacoeconomic analysis linked to the prevention of renal and vascular endstage disease (PREVEND) study and the prevention of renal and vascular endstage disease intervention tr (2006) (112)
Deletion-type allele of the angiotensin-converting enzyme gene is associated with progressive ventricular dilation after anterior myocardial infarction. Captopril and Thrombolysis Study Investigators. (1995) (111)
Angiotensin-(1–7) Attenuates Neointimal Formation After Stent Implantation in the Rat (2005) (109)
The deletion polymorphism of the angiotensin-converting enzyme gene is related to phenotypic differences in human arteries. (1996) (107)
Mortality and Morbidity Remain High Despite Captopril and/or Valsartan Therapy in Elderly Patients With Left Ventricular Systolic Dysfunction, Heart Failure, or Both After Acute Myocardial Infarction: Results From the Valsartan in Acute Myocardial Infarction Trial (VALIANT) (2005) (107)
Separating the Mechanism-Based and Off-Target Actions of Cholesteryl Ester Transfer Protein Inhibitors With CETP Gene Polymorphisms (2010) (104)
Association Between Chromosome 9p21 Variants and the Ankle-Brachial Index Identified by a Meta-Analysis of 21 Genome-Wide Association Studies (2012) (102)
Short-term vitamin D3 supplementation lowers plasma renin activity in patients with stable chronic heart failure: an open-label, blinded end point, randomized prospective trial (VitD-CHF trial). (2013) (102)
52 Genetic Loci Influencing Myocardial Mass. (2016) (98)
The effect of statins on urinary albumin excretion and glomerular filtration rate: results from both a randomized clinical trial and an observational cohort study. (2006) (98)
Genome-wide association study for circulating levels of PAI-1 provides novel insights into its regulation. (2012) (93)
Bradykinin Protects Against Oxidative Stress–Induced Endothelial Cell Senescence (2009) (92)
Qualitative examination of compliance in heart failure patients in The Netherlands. (2010) (92)
C-reactive protein and microalbuminuria are associated with atrial fibrillation. (2005) (90)
Eight blood pressure loci identified by genome-wide association study of 34,433 people of European ancestry (2009) (88)
Cardiac complications in patients hospitalised with COVID-19 (2020) (88)
Hemoglobin levels and 30-day mortality in patients after myocardial infarction. (2005) (87)
A Simple and Computationally Efficient Approach to Multifactor Dimensionality Reduction Analysis of Gene-Gene Interactions for Quantitative Traits (2013) (85)
Dual pathway for angiotensin II formation in human internal mammary arteries (1998) (82)
Circulating Rather Than Cardiac Angiotensin-(1-7) Stimulates Cardioprotection After Myocardial Infarction (2010) (82)
Predictors and outcomes of heart failure with mid‐range ejection fraction (2018) (81)
Captopril reduces purine loss and reperfusion arrhythmias in the rat heart after coronary artery occlusion. (1984) (81)
Carotid Intima-Media Thickness Progression as Surrogate Marker for Cardiovascular Risk (2020) (81)
Adequacy of endogenous erythropoietin levels and mortality in anaemic heart failure patients. (2008) (80)
Comparison of zofenopril and lisinopril to study the role of the sulfhydryl‐group in improvement of endothelial dysfunction with ACE‐inhibitors in experimental heart failure (2000) (80)
Which patient benefits from early angiotensin-converting enzyme inhibition after myocardial infarction? Results of one-year serial echocardiographic follow-up from the Captopril and Thrombolysis Study (CATS). (1996) (79)
Telomere biology in cardiovascular disease: the TERC-/- mouse as a model for heart failure and ageing. (2008) (78)
Causal Effect of Plasminogen Activator Inhibitor Type 1 on Coronary Heart Disease (2017) (78)
The importance of microalbuminuria as a cardiovascular risk indicator: A review. (2002) (74)
Rationale, design, and baseline characteristics of a trial of prevention of cardiovascular and renal disease with fosinopril and pravastatin in nonhypertensive, nonhypercholesterolemic subjects with microalbuminuria (the Prevention of REnal and Vascular ENdstage Disease Intervention Trial [PREVEND I (2000) (73)
Vascular endothelial growth factor is crucial for erythropoietin-induced improvement of cardiac function in heart failure. (2010) (73)
Selective and time related activation of the cardiac renin-angiotensin system after experimental heart failure: relation to ventricular function and morphology. (1993) (71)
Aging, telomeres and heart failure (2010) (68)
Clinical Risk Stratification Optimizes Value of Biomarkers to Predict New-Onset Heart Failure in a Community-Based Cohort (2014) (68)
Sustained postoperative anaemia is associated with an impaired outcome after coronary artery bypass graft surgery: insights from the IMAGINE trial (2011) (67)
Statins in the treatment of chronic heart failure: biological and clinical considerations. (2006) (67)
Optimization of ultrasound and microbubbles targeted gene delivery to cultured primary endothelial cells (2007) (66)
Angiotensin receptors in the cardiovascular system. (2002) (66)
Vitamin D biology in heart failure: molecular mechanisms and systematic review. (2011) (64)
Fibrosis Marker Syndecan-1 and Outcome in Patients With Heart Failure With Reduced and Preserved Ejection Fraction (2014) (64)
High prevalence of microalbuminuria in chronic heart failure patients. (2005) (64)
Microalbuminuria modifies the mortality risk associated with electrocardiographic ST-T segment changes. (2002) (64)
Endogenous Erythropoietin and Outcome in Heart Failure (2010) (62)
N-Acetyl-Ser-Asp-Lys-Pro Inhibits Phosphorylation of Smad2 in Cardiac Fibroblasts (2002) (62)
Concentration‐Dependent Protection by Captopril Against Myocardial Damage During Ischemia and Reperfusion in a Closed Chest Pig Model (1987) (61)
Effects of erythropoietin after an acute myocardial infarction: rationale and study design of a prospective, randomized, clinical trial (HEBE III). (2008) (61)
Differential influences of angiotensin converting‐enzyme inhibitors on the coronary circulation (1988) (61)
Impact of previous percutaneous transluminal coronary angioplasty and/or stenting revascularization on outcomes after surgical revascularization: insights from the imagine study. (2008) (60)
Endothelial Dysfunction in Patients With Coronary Artery Disease: A Comparison of Three Frequently Reported Tests (2002) (60)
Age-stratified and blood-pressure-stratified effects of blood-pressure-lowering pharmacotherapy for the prevention of cardiovascular disease and death: an individual participant-level data meta-analysis (2021) (60)
Decrease of right and left atrial sizes after direct-current electrical cardioversion in chronic atrial fibrillation. (1991) (59)
Unraveling the mechanisms for heart failure patients' beliefs about compliance. (2007) (59)
Telomere length and outcome in heart failure. (2010) (58)
Mild preoperative renal dysfunction as a predictor of long-term clinical outcome after coronary bypass surgery. (2005) (58)
Statins in the Treatment of Chronic Heart Failure: A Systematic Review (2006) (58)
Incidence and clinical significance of ST segment elevation after electrical cardioversion of atrial fibrillation and atrial flutter. (1991) (58)
Telomere length and psychological well-being in patients with chronic heart failure. (2010) (57)
Differences in Vasomotor Control Between Human Gastroepiploic and Left Internal Mammary Artery (1992) (54)
Cardiovascular end-organ damage in Ren-2 transgenic rats compared to spontaneously hypertensive rats (1997) (53)
Effects of flecainide on the atrial defibrillation threshold. (1989) (53)
Effects of Fosinopril and Pravastatin on Carotid Intima-Media Thickness in Subjects With Increased Albuminuria (2005) (53)
Flecainide versus quinidine in the prevention of paroxysms of atrial fibrillation. (1989) (52)
Cardiac LXRα protects against pathological cardiac hypertrophy and dysfunction by enhancing glucose uptake and utilization (2015) (52)
Caveolae and endothelial dysfunction: filling the caves in cardiovascular disease. (2008) (51)
A comparison of internal mammary artery and saphenous vein grafts after coronary artery bypass surgery. No difference in 1-year occlusion rates and clinical outcome. CABADAS Research Group of the Interuniversity Cardiology Institute of The Netherlands. (1994) (51)
Renal Handling of Galectin‐3 in the General Population, Chronic Heart Failure, and Hemodialysis (2014) (50)
Aprotinin in Aortocoronary Bypass Surgery: Increased Risk of Vein-Graft Occlusion and Myocardial Infarction? Supportive Evidence from a Retrospective Study (1996) (50)
Mild renal dysfunction is associated with electrocardiographic left ventricular hypertrophy. (2005) (50)
Increased expression of cardiac angiotensin II type 1 (AT(1)) receptors decreases myocardial microvessel density after experimental myocardial infarction. (2003) (49)
The effects of short- and long-term treatment with an ACE-inhibitor in rats with myocardial infarction. (1991) (49)
C-reactive protein and angiographic characteristics of stable and unstable coronary artery disease: data from the prospective PREVEND cohort. (2008) (49)
Rat Abdominal Aorta Stenting: A New and Reliable Small Animal Model for In-Stent Restenosis (2004) (48)
Genetic Determinants of P Wave Duration and PR Segment (2014) (48)
Potentiation of isosorbide dinitrate-induced coronary dilatation by captopril. (1987) (48)
Possible association between telomere length and renal dysfunction in patients with chronic heart failure. (2008) (48)
Impaired coronary endothelial function in a rat model of spontaneous albuminuria. (2002) (48)
Telomere Length of Circulating Leukocyte Subpopulations and Buccal Cells in Patients with Ischemic Heart Failure and Their Offspring (2011) (47)
Gender‐specific correlations of plasminogen activator inhibitor‐1 and tissue plasminogen activator levels with cardiovascular disease‐related traits (2007) (47)
Urinary albumin excretion is related to cardiovascular risk indicators, not to flow-mediated vasodilation, in apparently healthy subjects. (2002) (46)
Captopril‐Induced Increase in Coronary Flow: An SH‐Dependent Effect on Arachidonic Acid Metabolism? (1987) (46)
A role for CETP TaqIB polymorphism in determining susceptibility to atrial fibrillation: a nested case control study (2006) (45)
The gender-specific role of polymorphisms from the fibrinolytic, renin-angiotensin, and bradykinin systems in determining plasma t-PA and PAI-1 levels (2006) (45)
Converting Enzyme Inhibitors and the Role of the Sulfhydryl Group in the Potentiation of Exo‐ and Endogenous Nitrovasodilators (1991) (45)
Emerging role of liver X receptors in cardiac pathophysiology and heart failure (2015) (45)
Anemia is associated with bleeding and mortality, but not stroke, in patients with atrial fibrillation: Insights from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial (2017) (45)
Serial galectin-3 and future cardiovascular disease in the general population (2016) (44)
Vascular endothelial growth factor: the link between cardiovascular risk factors and microalbuminuria? (2004) (44)
The Plk1 Inhibitor BI 2536 Temporarily Arrests Primary Cardiac Fibroblasts in Mitosis and Generates Aneuploidy In Vitro (2010) (44)
Effect of intensive versus moderate lipid lowering on endothelial function and vascular responsiveness to angiotensin II in stable coronary artery disease. (2005) (44)
Clinical impact of vasomotor function assessment and the role of ACE-inhibitors and statins. (2005) (43)
Age dependent associations of risk factors with heart failure: pooled population based cohort study (2021) (43)
A Genome-Wide Association Study of Circulating Galectin-3 (2012) (42)
Identification of hypertrophy- and heart failure-associated genes by combining in vitro and in vivo models. (2012) (42)
Circulating Leukocyte and Carotid Atherosclerotic Plaque Telomere Length: Interrelation, Association With Plaque Characteristics, and Restenosis After Endarterectomy (2011) (42)
Attenuation of Renovascular Damage in Zucker Diabetic Fatty Rat by NWT-03, an Egg Protein Hydrolysate with ACE- and DPP4-Inhibitory Activity (2012) (41)
The emerging role of telomere biology in cardiovascular disease. (2010) (41)
Atrial Remodeling Is Directly Related to End-Diastolic Left Ventricular Pressure in a Mouse Model of Ventricular Pressure Overload (2013) (41)
Cyclical stretch induces structural changes in atrial myocytes (2013) (40)
Effects of Angiotensin II and Captopril on Inducible Sustained Ventricular Tachycardia Two Weeks After Myocardial Infarction in the Pig (1989) (40)
Long-term anti-ischemic effects of angiotensin-converting enzyme inhibition in patients after myocardial infarction. The Captopril and Thrombolysis Study (CATS) Investigators. (1997) (40)
Effects of Acetylsalicylic Acid on Peripheral Hemodynamics in Patients with Chronic Heart Failure Treated with Angiotensin‐Converting Enzyme Inhibitors (1994) (40)
Genome-Wide Association Study for Circulating Tissue Plasminogen Activator Levels and Functional Follow-Up Implicates Endothelial STXBP5 and STX2 (2014) (39)
Cardiac arrhythmias--a new indication for angiotensin-converting enzyme inhibitors? (1989) (39)
Angiotensin II Formation in Human Vasculature after Chronic ACE Inhibition: A Prospective, Randomized, Placebo-Controlled Study (2000) (39)
Protective effects of captopril against ischemia/reperfusion-induced ventricular arrhythmias in vitro and in vivo. (1988) (39)
Influence of age on the prognostic value of mid-regional pro-adrenomedullin in the general population (2012) (39)
Long-term effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria:Ten years of follow-up of Prevention of Renal and Vascular End-stage Disease Intervention Trial (PREVEND IT). (2011) (38)
The effect of cholesterol reduction on the endothelial function and progression of atherosclerosis in WHHL rabbits. (1993) (38)
Genome-Wide Association Study on Plasma Levels of Midregional-Proadrenomedullin and C-Terminal-Pro-Endothelin-1 (2013) (37)
Prediction of 6 months left ventricular dilatation after myocardial infarction in relation to cardiac morbidity and mortality. Application of a new dilatation model to GISSI-3 data. (2002) (37)
The role of the renin-angiotensin-aldosterone system in cardiovascular progenitor cell function. (2009) (37)
LXRα improves myocardial glucose tolerance and reduces cardiac hypertrophy in a mouse model of obesity-induced type 2 diabetes (2015) (37)
Addition of an angiotensin receptor blocker to full-dose ACE-inhibition: controversial or common sense? (2005) (36)
Early expression of natriuretic peptides and SERCA in mild heart failure: association with severity of the disease. (2001) (36)
Accumulation of 5-oxoproline in myocardial dysfunction and the protective effects of OPLAH (2017) (35)
Framingham score and microalbuminuria: combined future targets for primary prevention? (2004) (35)
Dissociation of blood pressure reduction from end‐organ damage in TGR(mREN2)27 transgenic hypertensive rats (1998) (34)
Chronic beta-blocker treatment in patients with advanced heart failure. Effects on neurohormones. (2000) (33)
Plasma renin and outcome in the community: data from PREVEND. (2012) (33)
Is the A1166C polymorphism of the angiotensin II type 1 receptor involved in cardiovascular disease? (1998) (33)
Low sodium diet inhibits the local counter-regulator effect of angiotensin-(1-7) on angiotensin II (2004) (32)
Basic pharmacology of ACE-inhibitors with respect to ischaemic heart disease: prostaglandins and bradykinin. (1990) (32)
Four Genetic Loci Influencing Electrocardiographic Indices of Left Ventricular Hypertrophy (2011) (32)
Plasma angiotensin-converting enzyme activity and left ventricular dilation after myocardial infarction. (1997) (32)
Increased risk for ischaemic events is related to combined RAS polymorphism (2001) (32)
Epistatic effects of polymorphisms in genes from the renin-angiotensin, bradykinin, and fibrinolytic systems on plasma t-PA and PAI-1 levels. (2007) (31)
Renal dysfunction is associated with shorter telomere length in heart failure (2009) (31)
Long-term outcome in men and women after CABG; results from the IMAGINE trial. (2015) (31)
Endothelium dependent relaxation in two different models of chronic heart failure and the effect of ibopamine. (1993) (31)
Genome-wide meta-analysis of common variant differences between men and women (2012) (31)
Anemia in chronic heart failure: etiology and treatment options (2008) (31)
Association of left ventricular remodeling and nonuniform electrical recovery expressed by nondipolar QRST integral map patterns in survivors of a first anterior myocardial infarction. Captopril and Thrombolysis Study Investigators. (1995) (31)
Left atrial pressure reduction for mitral stenosis reverses left atrial direction-dependent conduction abnormalities. (2010) (30)
Animal models of cardiorenal syndrome: a review (2011) (30)
Overexpression of A kinase interacting protein 1 attenuates myocardial ischaemia/reperfusion injury but does not influence heart failure development. (2016) (30)
Effects of aspirin on angiotensin-converting enzyme inhibition and left ventricular dilation one year after acute myocardial infarction. (1998) (29)
Monitoring Initial Response to Angiotensin-Converting Enzyme Inhibitor–Based Regimens: An Individual Patient Data Meta-Analysis From Randomized, Placebo-Controlled Trials (2010) (28)
Converting enzyme inhibition after experimental myocardial infarction in rats: comparative study between spirapril and zofenopril. (1991) (28)
Association between reduced heart rate variability and left ventricular dilatation in patients with a first anterior myocardial infarction. CATS Investigators. Captopril and Thrombolysis Study. (1994) (28)
Effect of very early angiotensin-converting enzyme inhibition on left ventricular dilation after myocardial infarction in patients receiving thrombolysis: results of a meta-analysis of 845 patients. FAMIS, CAPTIN and CATS Investigators. (2000) (28)
Heart failure-associated anemia: bone marrow dysfunction and response to erythropoietin (2010) (28)
Concentration-dependent protection by captopril against ischemia-reperfusion injury in the isolated rat heart. (1986) (27)
The liver X receptor agonist AZ876 protects against pathological cardiac hypertrophy and fibrosis without lipogenic side effects (2015) (27)
Suicidal erythrocyte death, eryptosis, as a novel mechanism in heart failure-associated anaemia. (2013) (27)
Sustained Protection by Iloprost of the Porcine Heart in the Acute and Chronic Phases of Myocardial Infarction (1985) (27)
Renal Mechanisms of Association between Fibroblast Growth Factor 1 and Blood Pressure. (2015) (27)
Cardioprotection by angiotensin-converting enzyme (ACE) inhibitors. (1993) (27)
Disruption of endothelial caveolae is associated with impairment of both NO- as well as EDHF in acetylcholine-induced relaxation depending on their relative contribution in different vascular beds. (2007) (27)
Genome-Wide Meta-Analyses of Plasma Renin Activity and Concentration Reveal Association With the Kininogen 1 and Prekallikrein Genes (2015) (26)
Effects of quinapril, losartan and hydralazine on cardiac hypertrophy and β‐adrenergic neuroeffector mechanisms in transgenic (mREN2)27 rats (1998) (26)
Beta-adrenergic signal transduction following carvedilol treatment in hypertensive cardiac hypertrophy. (1998) (26)
Inflammation and anaemia in a broad spectrum of patients with heart failure (2012) (26)
The Association of the Metabolic Syndrome with PAI-1 and t-PA Levels (2011) (25)
Differential inhibition of plasma versus tissue ACE by utibapril: biochemical and functional evidence for inhibition of vascular ACE activity. (1997) (25)
Antihypertensive treatment and risk of cancer: an individual participant data meta-analysis (2021) (25)
Prescribing for chronic heart failure in Europe: does the country make the difference? A European survey (2007) (24)
High fasting glucose and QTc duration in a large healthy cohort (2000) (24)
Exercise-Induced Ischemia after Successful Percutaneous Coronary Intervention Is Related to Distal Coronary Endothelial Dysfunction (2003) (23)
Long term angiotensin converting enzyme-inhibition in patients after coronary artery bypass grafting reduces levels of soluble intercellular cell adhesion molecule-1. (2003) (23)
Telomere length and outcomes in ischaemic heart failure: data from the COntrolled ROsuvastatin multiNAtional Trial in Heart Failure (CORONA) (2015) (23)
Erythropoietin in cardiac disease: new features of an old drug. (2008) (23)
Safety Evaluation of Routine Intracoronary Acetylcholine Infusion in Patients Undergoing a First Diagnostic Coronary Angiogram (2002) (23)
Vascular Response to Angiotensin II Predicts Long-Term Prognosis in Patients Undergoing Coronary Artery Bypass Grafting (2004) (23)
Age is the main determinant of COVID-19 related in-hospital mortality with minimal impact of pre-existing comorbidities, a retrospective cohort study (2021) (22)
Twenty-eight genetic loci associated with ST-T-wave amplitudes of the electrocardiogram (2016) (22)
Usefulness of preoperative C-reactive protein and soluble intercellular adhesion molecule-1 level for predicting future cardiovascular events after coronary artery bypass grafting. (2006) (22)
Loss of mitochondrial exo/endonuclease EXOG affects mitochondrial respiration and induces ROS-mediated cardiomyocyte hypertrophy. (2015) (21)
Dyslipidemia and endothelium-dependent relaxation in internal mammary arteries used for coronary bypass surgery. (1997) (21)
Hyperactive tissue renin-angiotensin systems in cardiovascular dysfunction: experimental evidence and clinical hypotheses. (1995) (21)
Effects of Ivabradine and Metoprolol on Cardiac Angiogenesis and Endothelial Dysfunction in Rats With Heart Failure (2009) (21)
Left ventricular assessment in myocardial infarction: the VALIANT registry. (2005) (21)
Improved functional recovery of the isolated rat heart after 24 hours of hypothermic arrest with a stable prostacyclin analogue (ZK 36 374). (1983) (20)
DD ACE gene polymorphism is associated with increased coronary artery endothelial dysfunction: the PREFACE trial (2003) (20)
Left ventricular dilatation after myocardial infarction: ACE inhibitors, beta-blockers, or both? (1998) (20)
A promising technique for transplantation of bone marrow-derived endothelial progenitor cells into rat heart. (2007) (20)
Reduction of exercise-induced myocardial ischemia during add-on treatment with the angiotensin-converting enzyme inhibitor enalapril in patients with normal left ventricular function and optimal beta blockade. (2001) (20)
Effect of ibopamine on ventricular remodeling after experimental myocardial infarction: a comparison with captopril. (1994) (20)
Renal function dependent association of AGTR1 polymorphism (A1166C) and electrocardiographic left-ventricular hypertrophy. (2007) (20)
Effects of Early Angiotensin-Converting Enzyme Inhibition in a Pig Model of Myocardial Ischemia and Reperfusion (1992) (20)
Can critically short telomeres cause functional exhaustion of progenitor cells in postinfarction heart failure? (2007) (20)
Trends in prescribing for heart failure in Dutch primary care from 1996 to 2000 (2003) (20)
Effect of withdrawal of pravastatin therapy on C-reactive protein and low-density lipoprotein cholesterol. (2007) (19)
Improved Recovery of Cardiac Function After 24 h of Hypothermic Arrest in the Isolated Rat Heart: Comparison of a Prostacyclin Analogue (ZK 36 374) and a Calcium Entry Blocker (Diltiazem) (1985) (19)
Mode of death in patients with congestive heart failure: comparison between possible candidates for heart transplantation and patients with less advanced disease. (1993) (19)
Perfusion-independent effect of bradykinin and fosinoprilate on glucose transport in Langendorff rat hearts. (1997) (19)
Prognostic value of renin and prorenin in heart failure patients with decreased kidney function. (2011) (19)
AKIP1 Expression Modulates Mitochondrial Function in Rat Neonatal Cardiomyocytes (2013) (19)
Proteinuria-Associated Endothelial Dysfunction Is Strain Dependent (2009) (19)
Renin-Angiotensin System Intervention to Prevent In-Stent Restenosis: An Unclosed Chapter (2005) (19)
Difference in the relation between urinary albumin excretion and carotid intima-media thickness in nondiabetic and type 2 diabetic subjects. (2002) (19)
Vascular Function and Mild Renal Impairment in Stable Coronary Artery Disease (2005) (18)
Vectors based on Semliki Forest virus for rapid and efficient gene transfer into non-endothelial cardiovascular cells: comparison to adenovirus. (1997) (18)
Vascular effects of quinapril completely depend on ACE insertion/deletion polymorphism (2004) (18)
AKIP1, a Cardiac Hypertrophy Induced Protein that Stimulates Cardiomyocyte Growth via the Akt Pathway (2013) (18)
Intradaily variation of the human lower leg length and short term growth--a longitudinal study in fourteen children. (1983) (18)
Nuclear hormone receptors as regulators of the renin-angiotensin-aldosterone system. (2008) (18)
Relation between albumin in the urine and electrocardiographic markers of myocardial ischemia in patients without diabetes mellitus. (2001) (18)
Beta-blocker titration failure is independent of severity of heart failure. (2000) (18)
Angiotensin converting enzyme inhibition in cardiovascular risk populations: a practical approach to identify the patient who will benefit most (2007) (18)
Vascular dysfunction in adriamycin nephrosis: different effects of adriamycin exposure and nephrosis. (2008) (18)
Renal function as a predictor of prognosis in chronic heart failure. (2002) (17)
Relation between myocardial beta-adrenoceptor density and hemodynamic and neurohumoral changes in a rat model of chronic myocardial infarction: effects of ibopamine and captopril. (1995) (17)
Genetic architecture of tissue-type plasminogen activator and plasminogen activator inhibitor-1. (2008) (17)
Efficacy of Angiotensin II Type 1 Receptor Blockade on Reperfusion-Induced Arrhythmias and Mortality Early After Myocardial Infarction Is Increased in Transgenic Rats With Cardiac Angiotensin II Type 1 Overexpression (2002) (17)
Captopril modifies the response of infarcted rat hearts to isoprenaline stimulation. (1992) (16)
Variable effects of anti-diabetic drugs in animal models of myocardial ischemia and remodeling: a translational perspective for the cardiologist. (2013) (16)
Hypertrophy induced KIF5B controls mitochondrial localization and function in neonatal rat cardiomyocytes. (2016) (16)
[Telomeres and biological ageing in cardiovascular disease]. (2008) (16)
Left ventricular dilatation and high-grade ventricular arrhythmias in the first year after myocardial infarction. CATS Investigators. Captopril and Thrombolysis Study. (1994) (15)
Predictors of Angiotensin-Converting Enzyme Inhibitor–Induced Reduction of Urinary Albumin Excretion in Nondiabetic Patients (2006) (15)
Effects of lacidipine on peak oxygen consumption, neurohormones and invasive haemodynamics in patients with mild to moderate chronic heart failure. (1996) (15)
Hemoglobin levels and new-onset heart failure in the community. (2015) (15)
Effects of diltiazem on reperfusion-induced arrhythmias in vitro and in vivo. (1986) (15)
High serum erythropoietin levels are related to heart failure development in subjects from the general population with albuminuria: data from PREVEND (2016) (15)
The Cardiovascular Research community calls for action to address the growing burden of cardiovascular disease. (2019) (15)
Different effects of bisoprolol on heart rate in patients with ischemic or idiopathic dilated cardiomyopathy (a 24-hour Holter substudy of the Cardiac Insufficiency Bisoprolol Study [CIBIS]). (1999) (14)
Erythropoietin in chronic heart failure. (2007) (14)
Dietary sodium restriction specifically potentiates left ventricular ACE inhibition by zofenopril, and is associated with attenuated hypertrophic response in rats with myocardial infarction (2004) (14)
Effects of intravenous captopril on inducible sustained ventricular tachycardia one week after experimental infarction in the anaesthetized pig. (1986) (14)
Impact of statins in microalbuminuric subjects with the metabolic syndrome: a substudy of the PREVEND Intervention Trial. (2005) (14)
Early intervention with angiotensin-converting enzyme inhibitors during thrombolytic therapy in acute myocardial infarction: rationale and design of captopril and thrombolysis study. CATS investigators group. (1991) (14)
Long-term follow-up after early intervention with intravenous diltiazem or intravenous nitroglycerin for unstable angina pectoris. (1998) (13)
Intrinsic sympathomimetic activity (ISA) of pindolol in patients with sinus node dysfunction. (1986) (13)
Cardiac Function and Architecture Are Maintained in a Model of Cardiorestricted Overexpression of the Prorenin-Renin Receptor (2014) (13)
Heart failure guidelines and prescribing in primary care across Europe (2005) (13)
Recombinant Semliki Forest virus as a vector system for fast and selective in vivo gene delivery into balloon-injured rat aorta (2002) (13)
Assessing the prognostic value of coronary endothelial function in patients referred for a first coronary angiogram. (2004) (13)
Identification of a specific pattern of downregulation in expression of isoforms of vascular endothelial growth factor in dilated cardiomyopathy (2002) (13)
Sample dilution: a methodological pitfall in the measurement of tissue but not serum ace-activity. (1998) (13)
Statin Effects on Metabolic Profiles: Data From the PREVEND IT (Prevention of Renal and Vascular End-stage Disease Intervention Trial) (2017) (13)
Long-term effects of pravastatin and fosinopril on peripheral endothelial function in albuminuric subjects. (2006) (13)
Effects of angiotensin II and angiotensin II type 1 receptor blockade on neointimal formation after stent implantation. (2008) (13)
The role of coronary endothelial function testing in patients suspected for angina pectoris. (2004) (13)
Hydrochlorothiazide increases plasma or tissue angiotensin-converting enzyme-inhibitor drug levels in rats with myocardial infarction: differential effects on lisinopril and zofenopril. (2005) (12)
Effects of streptokinase during acute myocardial infarction on the signal-averaged electrocardiogram and on the frequency of late arrhythmias. (1993) (12)
The renin-angiotensin system and vascular function. The role of angiotensin II, angiotensin-converting enzyme, and alternative conversion of angiotensin I. (1997) (12)
Use of microdialysis for monitoring sympathetic and parasympathetic innervation of heart in conscious rats. (1997) (12)
Cardiovascular Risk Associated with Interactions among Polymorphisms in Genes from the Renin-Angiotensin, Bradykinin, and Fibrinolytic Systems (2010) (12)
β-blocker Therapy is Not Associated with Reductions in Angina or Cardiovascular Events After Coronary Artery Bypass Graft Surgery: Insights from the IMAGINE Trial (2015) (12)
Effects of ibopamine on the increase in plasma norepinephrine levels during exercise in congestive heart failure. (1993) (12)
Effects of converting enzyme inhibitors on coronary flow and myocardial ischemia. (1992) (12)
Time of symptom onset and value of myocardial blush and infarct size on prognosis in patients with ST-elevation myocardial infarction (2014) (12)
Flecainide acetate in the treatment of supraventricular tachycardias: value of programmed electrical stimulation for long-term prognosis. (1989) (12)
Rosuvastatin attenuates angiotensin II-induced neointimal formation after stent implantation in the rat (2006) (12)
Non-Bone Marrow Origin of Neointimal Smooth Muscle Cells in Experimental In-Stent Restenosis in Rats (2008) (11)
Plasma calcidiol, calcitriol, and parathyroid hormone and risk of new onset heart failure in a population‐based cohort study (2016) (11)
Progression of conventional cardiovascular risk factors and vascular disease risk in individuals: insights from the PROG-IMT consortium (2019) (11)
The ACE gene polymorphism: the good, the bad and the ugly. (1999) (11)
The impact of coronary artery disease risk loci on ischemic heart failure severity and prognosis: association analysis in the COntrolled ROsuvastatin multiNAtional trial in heart failure (CORONA) (2014) (11)
Improvement of EDHF by Chronic ACE Inhibition Declines Rapidly After Withdrawal in Rats With Myocardial Infarction (2005) (11)
Effects of C-reactive protein and cholesterol on responsiveness in vitro of the internal thoracic artery to angiotensin II in patients having coronary artery bypass grafting. (2006) (11)
Interaction of the renin-angiotensin system and the endothelin system in cardiac hypertrophy. (1998) (11)
The angiotensin converting enzyme inhibitor perindopril improves survival after experimental myocardial infarction in pigs. (1992) (11)
Leukocyte telomere length and left ventricular function after acute ST-elevation myocardial infarction: data from the glycometabolic intervention as adjunct to primary coronary intervention in ST elevation myocardial infarction (GIPS-III) trial (2015) (10)
Angiotensin II Type 2 Receptor Vasoactivity in Internal Mammary Arteries of Patients With Coronary Artery Disease (2007) (10)
Determinants of temporal changes in galectin-3 level in the general population: Data of PREVEND. (2016) (10)
The effects of bradykinin and the ischemic isolated rat heart. (1990) (10)
Clinical and neurohumoral differences between spirapril and captopril in mild to moderate chronic congestive heart failure. (1997) (10)
Rationale and design of the PRAETORIAN-COVID trial: A double-blind, placebo-controlled randomized clinical trial with valsartan for PRevention of Acute rEspiraTORy dIstress syndrome in hospitAlized patieNts with SARS-COV-2 Infection Disease (2020) (10)
Rat abdominal aortic stenting: a simple model displaying in-stent restenosis. (2002) (10)
Coronary vasomotor response is related to the angiographic extent of coronary sclerosis in patients with stable angina pectoris. (2004) (10)
Telomere length and outcome in heart failure (2008) (9)
Differential localisation of the renin-angiotensin system in de-novo lesions and in-stent restenotic lesions in in-vivo human coronary arteries. (2003) (9)
Functional Antagonism of Different Angiotensin II Type I Receptor Blockers in Human Arteries (2002) (9)
Relation of electrocardiographic abnormalities to levels of serum C-reactive protein. (2003) (8)
Direct interaction between the sympathetic and renin-angiotensin system in myocardial tissue: a microdialysis study in anaesthetised rats. (2000) (8)
Oral Anticoagulation in the Prevention of One-Year Vein Graft Occlusion after Aortocoronary Bypass Surgery: Optimal Therapeutic Range and Practical Limitations (1994) (8)
Anaemia predicts cardiovascular events in patients with stable coronary artery disease. (2005) (8)
Semliki Forest virus is an efficient and selective vector for gene delivery in infarcted rat heart. (2004) (8)
Measurement of coronary calcium scores or exercise testing as initial screening tool in asymptomatic subjects with ST-T changes on the resting ECG: an evaluation study (2007) (8)
Late potentials, QTc prolongation, and prediction of arrhythmic events after myocardial infarction. (1994) (8)
Angiotensin-converting enzyme inhibition in patients with coronary artery disease and preserved left ventricular function Ischemia Management with Accupril post-bypass graft via inhibition of angiotensin-converting enzyme (IMAGINE) compared with the other major trials in coronary artery disease. (2006) (8)
Differences Between Angiotensin-Converting Enzyme Inhibition and Angiotensin II-AT1 Antagonism on Angiotensin-Mediated Responses in Human Internal Mammary Arteries (2003) (8)
Effects of amlodipine on endothelial function in rats with chronic heart failure after experimental myocardial infarction. (1997) (8)
Blood pressure-lowering treatment for prevention of major cardiovascular diseases in people with and without type 2 diabetes: an individual participant-level data meta-analysis (2022) (7)
High Angiotensin II Responsiveness is Associated with Decreased Endothelium-Dependent Relaxation in Human Arteries (2005) (7)
Early pharmacologic intervention may prevent the deterioration in endothelial function after experimental myocardial infarction in rats: effects of ibopamine and captopril. (1997) (7)
Direct vasodilating effects of the new dopaminergic agonist Z1046 in human arteries. (2000) (7)
Thoracoscopic monitoring for pericardial application of local drug or gene therapy. (2002) (7)
Hypertension and left ventricular hypertrophy in black people. (1995) (7)
Acute hemodynamic and long-term clinical effects of isradipine in patients with coronary artery disease and chronic heart failure. A double-blind, placebo-controlled study. (1996) (7)
The erythropoietin receptor expressed in skeletal muscle is essential for mitochondrial biogenesis and physiological exercise (2021) (7)
Neurocardiology: close interaction between heart and brain (2012) (6)
Plasma matrix metalloproteinase-9 and ACE-inhibitor-induced improvement of urinary albumin excretion in non-diabetic, microalbuminuric subjects (2007) (6)
The Acute Hemodynamic, Hormonal, and Pharmacokinetic Properties of Oral Spirapril in Patients with Moderate to Severe Heart Failure (1991) (6)
Molecular adaptations in human atrial fibrillation: mechanisms of protein remodelling. (2001) (6)
Beta-adrenoceptor density in chronic infarcted myocardium: a subtype specific decrease of beta1-adrenoceptor density. (2000) (6)
Effects of Spirapril and Captopril on Regional Blood Flow in Chronic Congestive Heart Failure: A Comparison Between a Short- and a Long‐Acting Angiotensin‐Converting Enzyme Inhibitor (1995) (6)
Myocardial infarction with aortic banding. A combined rat model of heart failure. (1997) (6)
Dosing of ACE inhibitors in left ventricular dysfunction: does current clinical dosing provide optimal benefit? (1999) (6)
Effect of Isradipine and Nifedipine on Diastolic Function in Patients with Left Ventricular Dysfunction Due to Coronary Artery Disease: A Randomized, Double‐Blind, Nuclear, Stethoscope Study (1994) (5)
The German Centre for Cardiovascular Research. (2012) (5)
Digital arterial pressure pulse wave analysis and cardiovascular events in the general population: the Prevention of Renal and Vascular End-stage Disease study. (2020) (5)
The pharmacological management of heart failure: too many treatments? (2003) (5)
Drug Differences between ACE Inhibitors in Experimental Settings and Clinical Practice (1995) (5)
Serum potassium values in relation to the use of diuretics in patients with unstable angina pectoris. (1988) (4)
Vasopeptidase inhibition in heart failure. (2000) (4)
Genotype-dependent increase in plasma ACE activity after CABG is prevented by ACE inhibition. (2003) (4)
The increase in coronary flow induced by converting enzyme inhibitors is prostacyclin independent. (1989) (4)
Improvement of endothelial dysfunction in experimental heart failure by chronic RAAS-blockade: ACE-inhibition or AT1-receptor blockade? (2001) (4)
Ibopamine-induced reversible leukopenia during treatment for congestive heart failure. (1993) (4)
Calcium antagonism in perspective: new data on diltiazem in unstable angina. (1996) (4)
Biphasic positive inotropic actions of ouabain on rat, guinea-pig and cat heart: a mathematical description. (1984) (4)
The haemodynamic effects of two angiotensin converting enzyme inhibitors, enalaprilat and zofenoprilat, in the rat: evidence for the involvement of bradykinin. (1989) (4)
Review: The revised role of ACE-inhibition after myocardial infarction in the thrombolytic/primary PCI era (2004) (4)
The oral dopamine agonist, ibopamine, in normal man: effects on rhythm, heart rate, blood pressure and catecholamines. (1991) (3)
Flecainide: Long‐Term Effects in Patients with Sustained Ventricular Tachycardia or Ventricular Fibrillation (1990) (3)
Effects of selective dopaminergic receptor stimulation on ventricular remodeling after experimental myocardial infarction in rats. (1997) (3)
Triggered activity as arrhythmogenic mechanism after myocardial infarction: Clinical and electrophysiologic study of one case (1992) (3)
Angiotensin-converting enzyme inhibition during thrombolytic therapy in acute myocardial infarction: the Captopril and Thrombolysis Study (CATS). (1993) (3)
Fibroblast Growth Factor 23 and Risk of New Onset Heart Failure With Preserved or Reduced Ejection Fraction: The PREVEND Study (2022) (3)
Determination of vessel size: a putative framework to assess clinical outcome. (2005) (3)
Adverse renal effects of hydrochlorothiazide in rats with myocardial infarction treated with an ACE inhibitor. (2006) (3)
The effect of bradykinin on coronary flow and its potentiation by SH-containing ACE-inhibitors. (1992) (3)
Erythropoiesis stimulation in acute ischemic syndromes. (2010) (2)
Interethnic analyses of blood pressure loci in populations of East Asian and European descent (2018) (2)
Einthoven dissertation prizes 2012 (2010) (2)
Neurohumoral changes and the inducibility of ventricular tachycardias: effect of early reperfusion on the ischemic porcine myocardium. (1992) (2)
Letter regarding article by Arnlov et al, "low-grade albuminuria and incidence of cardiovascular disease events in nonhypertensive and nondiabetic individuals". (2006) (2)
Einthoven dissertation prize 2010. (2010) (2)
Effect of fosinopril treatment on serum C-reactive protein levels in patients with microalbuminuria. (2008) (2)
Xamoterol in autonomic and intrinsic sinus node dysfunction. (1990) (2)
A simple, inexpensive, rapid, and accurate preclinical model for in-stent restenosis. (2005) (2)
A comparison of the cold pressor test and the diving test or coronary and systemic hemodynamics in patients with and without coronary artery disease. (1999) (2)
Early ACE-inhibition in myocardial infarction. Possible role of bradykinin. (1992) (1)
[The use of positron emission tomography in cardiology; a metabolic dimension]. (1991) (1)
[Value of basic and intensive management of patients with heart failure; results of a randomised controlled clinical trial]. (2008) (1)
Urinary albumin excretion and carotid intima-media thickness. (2005) (1)
[Statins: for the time being, do not as a rule prescribe the maximum dose]. (2005) (1)
Digital arterial pressure pulse wave analysis and cardiovascular events in the general population: the Prevention of Renal and Vascular End-stage Disease study (2020) (1)
Pectins from various sources inhibit galectin-3-related cardiac fibrosis (2022) (1)
Unravelling the Difference Between Men and Women in Post-CABG Survival (2022) (1)
Angiographic left ventricular wall motion score to predict arrhythmia recurrence in patients with sustained ventricular tachycardia or fibrillation (1996) (1)
Influence of Intravenous Diltiazem on Left Ventricular Function in Patients with Severe Coronary Artery Disease at Rest and During Pacing, Monitored by Computer‐Processed Nuclear Probe and Tip‐Manometer Data (1993) (1)
Protection of the Myocardium Against Postischemic Reperfusion Damage (1989) (1)
[Beta-blocking drugs indicated in patients with heart failure]. (2003) (1)
[Hormonal supplement therapy in women: effects on the cardiovascular system]. (2001) (1)
A concentration-dependent biphasic positive inotropic action of ouabain on isolated heart of rat and guinea-pig. (1982) (0)
Pre-procedural ACE-activity does not predict symptomatic in-stent restenosis. (2005) (0)
Use of microdialysis for monitoring sympathetic and parasympathetic innervation of heart in conscious rats. (1997) (0)
Unexpected news from the scientific sessions of the American College of Cardiology. (2002) (0)
Transitions across Kidney Disease Stages and Association with New-onset Heart Failure: a Population-Based study of 8569 Individuals and 12.6 Years of Follow-up (2023) (0)
Current insights and new treatment options in heart failure. (1998) (0)
Galectin-3 and Blood Group: Binding Properties, Effects on Plasma Levels, and Consequences for Prognostic Performance (2023) (0)
A Kinase Interacting Protein 1 (AKIP1) promotes cardiomyocyte elongation and physiological cardiac remodelling (2023) (0)
Beta-adrenergic blockade and heart rate. (1995) (0)
Heart failure: chapter 1. Pathophysiology and molecular aspects of heart failure. (2004) (0)
Anemia and erythropoietin in heart failure. (2008) (0)
[Not Available]. (2011) (0)
Anemia and congestive heart failure. (2003) (0)
Aggressive lipid-lowering therapy and regression of coronary atheroma. (2004) (0)
Treating Microalbuminuria-Cosmetic Exercises with Urine Chemistry or Effective Reduction of Clinical Events?: Effects of Fosinopril and Pravastatin on Cardiovascular Events in Subjects with Microalbuminuria. Circulation 110: 2809-2816, 2004. (2005) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Wiek H. Van Gilst?

Wiek H. Van Gilst is affiliated with the following schools:

University of Groningen

Wiek H. Van Gilst's Academic­Influence.com Rankings